Direct Presentation of Tumor‐Associated Antigens to Induce Adaptive Immunity by Personalized Dendritic Cell‐Mimicking Nanovaccines
Abstract Dendritic cells (DCs)‐based vaccines are an approved method for inducing potent antigen‐specific immune responses to eliminate tumor cells. However, this promising strategy still faces challenges such as tumor‐associated antigens (TAAs) loading, lymph node homing, quality control, and other limitations. Here, a personalized DC‐mimicking nanovaccine (nanoDC) for stimulation of TAAs‐specific T cell populations is developed. The nanoDCs are fabricated using nanoparticles with dendritic structure and membranes from mature bone‐marrow‐derived cells (BMDCs). Mature BMDCs are stimulated by nanostructures assembled from Escherichia coli and tumor cells to efficiently deliver TAAs and induce BMDCs maturation through the stimulator of interferon genes (STING) pathway. By maintaining co‐stimulatory markers, molecules class I (MHC‐I) antigen complexes and lymphocyte homing receptors, nanoDCs efficiently migrate to lymph nodes and generate potent antigen‐specific T cell responses. Consequently, vaccination with nanoDCs strongly inhibits the tumor growth and metastases formation in vivo. In particular, nanoDCs can also induce memory T cells for long‐term protective immunity. This study demonstrates that nanoDCs can trigger adaptive immune protection against tumors for personalized immunotherapy and precision medicine..
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:34 |
|---|---|
| Enthalten in: |
Advanced Materials - 34(2022), 47 |
| Beteiligte Personen: |
Zhang, Jie [VerfasserIn] |
|---|
| BKL: |
|---|
| Anmerkungen: |
© 2022 Wiley‐VCH GmbH |
|---|
| Umfang: |
13 |
|---|
| doi: |
10.1002/adma.202205950 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
WLY000331317 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | WLY000331317 | ||
| 003 | DE-627 | ||
| 005 | 20230307090713.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 230209s2022 xx |||||o 00| ||und c | ||
| 024 | 7 | |a 10.1002/adma.202205950 |2 doi | |
| 028 | 5 | 2 | |a ADMA_ADMA202205950.xml |
| 035 | |a (DE-627)WLY000331317 | ||
| 035 | |a (WILEY)ADMA202205950 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rda | ||
| 082 | 0 | 4 | |a 540 |a 660 |q ASE |
| 084 | |a 51.45 |2 bkl | ||
| 100 | 1 | |a Zhang, Jie |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Direct Presentation of Tumor‐Associated Antigens to Induce Adaptive Immunity by Personalized Dendritic Cell‐Mimicking Nanovaccines |
| 264 | 1 | |c 2022 | |
| 300 | |a 13 | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a © 2022 Wiley‐VCH GmbH | ||
| 520 | |a Abstract Dendritic cells (DCs)‐based vaccines are an approved method for inducing potent antigen‐specific immune responses to eliminate tumor cells. However, this promising strategy still faces challenges such as tumor‐associated antigens (TAAs) loading, lymph node homing, quality control, and other limitations. Here, a personalized DC‐mimicking nanovaccine (nanoDC) for stimulation of TAAs‐specific T cell populations is developed. The nanoDCs are fabricated using nanoparticles with dendritic structure and membranes from mature bone‐marrow‐derived cells (BMDCs). Mature BMDCs are stimulated by nanostructures assembled from Escherichia coli and tumor cells to efficiently deliver TAAs and induce BMDCs maturation through the stimulator of interferon genes (STING) pathway. By maintaining co‐stimulatory markers, molecules class I (MHC‐I) antigen complexes and lymphocyte homing receptors, nanoDCs efficiently migrate to lymph nodes and generate potent antigen‐specific T cell responses. Consequently, vaccination with nanoDCs strongly inhibits the tumor growth and metastases formation in vivo. In particular, nanoDCs can also induce memory T cells for long‐term protective immunity. This study demonstrates that nanoDCs can trigger adaptive immune protection against tumors for personalized immunotherapy and precision medicine. | ||
| 700 | 1 | |a Fan, Biao |4 aut | |
| 700 | 1 | |a Cao, Guoliang |4 aut | |
| 700 | 1 | |a Huang, Wenping |4 aut | |
| 700 | 1 | |a Jia, Fuhao |4 aut | |
| 700 | 1 | |a Nie, Guangjun |4 aut | |
| 700 | 1 | |a Wang, Hai |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Advanced Materials |g 34(2022), 47 |w (DE-627)WLY00026945X |x 15214095 |7 nnns |
| 773 | 1 | 8 | |g volume:34 |g year:2022 |g number:47 |g extent:13 |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_WLY | ||
| 936 | b | k | |a 51.45 |q ASE |
| 951 | |a AR | ||
| 952 | |d 34 |j 2022 |e 47 |g 13 | ||